Navigation Links
Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Company's Phase III FDA Sickle Cell Treatment Trials
Date:11/19/2012

TORRANCE, Calif., Nov. 19, 2012 /PRNewswire/ -- Following a meeting on November 5, 2012 with the U.S. Food & Drug Administration (FDA), Dr. Yutaka Niihara offered the following remarks:

"The FDA's review group unanimously recommended that we proceed to complete our Phase III trial without any modification to the protocol. The trial is directed to study L-glutamine as a treatment for sickle cell disease.

"We currently have 220 patients enrolled at 32 study sites throughout the United States.  We will continue enrollment until the end of 2012, with an objective to complete the trial in 2013.

"The FDA's recommendation on proceeding to complete the trial follows the preliminary review of a subset of data from the Phase III clinical trial that was completed by an independent third party in August of this year.  Emmaus received its initial authorization from the FDA to begin the Phase III trial in August 2009, with the first patient enrolled in mid-2010.

"We continue to believe that Emmaus is the only company with a Phase III trial underway for a new sickle cell treatment.  With research grants and through the support of friends, family and private investors over the past 20 years, we have progressed to the point where we are confident in our treatment and hopeful it will be in the hands of patients worldwide in the not too distant future."

About Emmaus Medical, Inc.

Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase III clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine technology products. For more information, please visit '/>"/>

SOURCE Emmaus Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
2. Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
5. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
6. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
7. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
11. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014 /PRNewswire/ ... addressing the unmet needs of severely obese patients, ... study of beloranib, a selective inhibitor of methionine ... (PWS), a severe form of genetic obesity.  These ... and body composition, including reductions in body fat ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . ... of less invasive, miniaturized circulatory support technologies that ... today announced that it expects revenues for the ... million, bringing expected full-year 2013 revenues to approximately ... of 87% for 2013 above 2012 reflects the ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, ... for buyers and sellers of high-value chemistry, will hold ... at the Miami Beach Convention ... ) More than 3,500 attendees from ... take part in the conference, which includes on-site education ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Imagenetix, Inc. (OTC Bulletin Board: IAGX ) announced today ... Net sales decreased 4% for the third quarter of fiscal year ... year. A loss of $1,202,000, $0.10 per share, was reported for ... loss of $294,000, $.03 per share, for the same period of ...
... Feb. 25, 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China ... and markets specialty pharmaceutical products in China, today announced that ... before the market opens on Thursday, March 3, 2011. ... 8:30 am ET on March 3, 2011 to discuss fiscal ...
Cached Medicine Technology:Imagenetix, Inc. Reports Third Quarter 2011 Results 2Imagenetix, Inc. Reports Third Quarter 2011 Results 3China Pharma Holdings, Inc. to Report Fiscal Year 2010 Financial Results on March 3, 2011 2
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
(Date:4/14/2014)... aren,t breastfed or not breastfed for long are ... related health problems later in life, according to ... to hypothesize that breastfeeding was important to influencing ... (Northwestern University), a CIFAR (Canadian Institute for Advanced ... program. "It changes the microbiome. It promotes development ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Low birth weight, less breastfeeding create later health risks 2
... how hypertension is treated, experts say , SUNDAY, March ... large five-year study points to fluctuations in blood pressure ... , In the study, British researchers tracked the health ... or calcium channel blocker medication to curb high blood ...
... traditional screening tests for potential anti-cancer drugs, scientists ... technique that more closely simulates the real-world conditions ... normal cells. Because these neighboring cells key ... microenvironment" can alter the effectiveness of anti-cancer ...
... fewer side effects than the conventional medication used during a ... a Henry Ford Hospital study. Researchers say the 25 ... such as abnormally low blood pressure or slow heart beat ... Additionally, patients showed no signs of heart block, a condition ...
... exam, study finds , SUNDAY, March 14 (HealthDay News) -- ... and collegiate hockey players in a U.S. study had abnormal ... see if abnormal MRI results are found incidentally in active ... the department of family medicine and orthopedics at Hershey Medical ...
... no effect in shielding users from cardiovascular woes, study ... that two available drugs could help prevent diabetes and ... sugar metabolism have been dashed by a major international ... other reasons -- Diovan (valsartan), a blood pressure medication; ...
... pressure to normal levels below currently recommended levels ... fatal or nonfatal cardiovascular disease events in adults with ... for cardiovascular disease events, according to new results from ... (ACCORD) clinical trial. Similarly, treating multiple blood lipids with ...
Cached Medicine News:Health News:More Evidence That Swings in Blood Pressure Raise Stroke Risk 2Health News:New cancer drug screening technique more closely mirrors reality 2Health News:New cancer drug screening technique more closely mirrors reality 3Health News:Scans May Be Misleading for Hockey Players 2Health News:2 Drugs Fail to Prevent Diabetes in the Overweight 2Health News:2 Drugs Fail to Prevent Diabetes in the Overweight 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The BD Macro-Vue RPR (Rapid Plasma ... Tear-drop Tests are nontreponemal testing procedures ... described in A Manual of Tests ... this manual are the most widely ...
Agglutination test on slide for qualitative and quantitative determination of Syphilis in serum or plasma....
... quality assurance reagent in assays detecting IgG and ... TOXO IgM), IgG and IgM antibodies to rubella ... IgM antibodies to cytomegalovirus (CMV IgG and IgM), ... virus types 1 and 2 (HSV-1 IgG, HSV-1 ...
Medicine Products: